Search for: "C. Ester" Results 41 - 60 of 85
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Aug 2019, 4:00 am by Administrator
Intitulé : Enerkem Alberta Biofuels c. [read post]
24 Feb 2021, 4:03 pm by José Guillermo
En la década de 1950, hace famosa en el Perú la canción Mambo de Machaguay.3​ En 1951 se casa con María Ester Colina Bailey de Abanto con quien tuvo 4 hijos. [read post]
22 Feb 2023, 1:42 pm by Courtenay C. Brinckerhoff
The opinion characterizes the decision in Natural Alternatives as being based on a conclusion that “the patents there claimed ‘specific treatment formulations that incorporate[d] natural products’ and that those formulations ‘ha[d] different characteristics and c[ould] be used in a manner that beta-alanine as it appears in nature cannot. [read post]
23 May 2014, 6:08 pm
Controlled-release oral pharmaceutical compositions containing as an active ingredient 5-amino-salicylic acid, comprising:a) an inner lipophilic matrix consisting of substances selected from the group consisting of unsaturated and/or hydrogenated fatty acid, salts, esters or amides thereof, fatty acid mono-, di- or triglycerid[e]s, waxes, ceramides, and cholesterol derivatives with melting points below 90° C., and wherein the active ingredient is dispersed both in said the… [read post]
22 Feb 2021, 11:45 am by Rebecca Tushnet
A: It could—he sees Minaj as definitely within scope b/c it’s not substitutional copying. [read post]
10 May 2011, 3:01 pm by Oliver G. Randl
A transdermal therapeutic system (ITS) consisting of an active compound-impermeable back layer, at least one matrix layer based on polyacrylate and comprising fentanyl, and a protective layer to be removed before use, characterized in that the polyacrylate is self-adhesive and free of carboxyl groups, is synthesized only from monomeric esters of alcohols comprising 1 to 8 C atoms, the alcohols having optionally a hydroxyl group, and of acrylic and/or methacrylic acid and, if… [read post]
30 Jul 2012, 7:39 pm by FDABlog HPM
  DEA’s administrative scheduling of prostanozol and methasterone, along with their salts, esters and ethers, becomes effective August 29, 2012. [read post]
4 Aug 2011, 3:01 pm by Oliver G. Randl
Compounds wherein the C=O or the C=S group of the benzo(thio)pyranone or benzo(thio)pyranthione had been alkylated were never considered by the ED. [read post]
12 Sep 2012, 5:09 am
Por meio de Ação Cível Originária (ACO 1966), o estado pretendia anular o tombamento do centro histórico de Manaus por vícios na trami [read post]
16 May 2021, 4:05 pm by Marco Rossi
Il rapporto avrebbe ad oggetto funzioni di alta amministrazione, in aggiunta alla carica di componente del consiglio di amministrazione di alcune società estere del gruppo. [read post]
17 Apr 2019, 7:28 am by Jessica Kroeze
C J J C van Nispen, dated 19 December 2018.D33: The Paris Convention Centenary, wipo-pub-875, ISBN 92-805-0099-6, WIPO 1983, pages 5, 15, 16, 27 to 31.D34: Bodenhausen, Guide to the application of the Paris Convention for the protection of industrial property, BIRPI 1968, pages 35 to 38.It further requested that two questions be referred to the Enlarged Board of Appeal (see below) or, alternatively, that a correction be allowed under Rule 139 EPC (see below). [read post]
16 Dec 2008, 11:47 pm
  This compound has the chemical name methyl alpha-5(4,5,6,7-tetrahydro(3,2-c)thieno pyridyl)(2-chlorophenyl)-acetate, with the acronym MATTPCA. [read post]
1 Aug 2011, 3:01 pm by Oliver G. Randl
In the examples (Table 1), an amount of acid of 0.5 wt.% is illustrated.[4.3] Claim 1 as granted thus encompasses any hair cleansing composition comprising 0.01 to 20 wt.% of component (A), 0.01 to 5 wt.% of component (B) and 5 to 40 wt.% of component (C). [read post]
19 Jun 2015, 12:00 am by Giorgio Buono
After having outlined the path that led to the adoption of the Directive and showed the need to modernise Union law in this area, this article analyses a) the European Professional Card; b) partial access; c) professional traineeship; d) common training principles; and e) the further most important revisions of Directive 2005/36/EC aiming at promoting the free movement of professionals. [read post]
20 Jul 2011, 8:34 pm by FDABlog HPM
  The statutory 5-year NCE exclusivity provision at FDC Act § 505(j)(5)(F)(ii) applicable to ANDAs (there is a slightly different parallel provision at FDC Act § 505(c)(3)(E)(ii) applicable to 505(b)(2) applications) governing the scope of NCE exclusivity states in relevant part: If an application submitted under subsection (b) for a drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application… [read post]
4 Jul 2011, 3:01 pm by Oliver G. Randl
This approach also has to be applied in first-instance proceedings (see the “Guidelines for Examination in the EPO”, part C-IV). [read post]
8 Jun 2011, 3:01 pm by Oliver G. Randl
The ground for opposition under A 100(c) therefore does not prejudice the maintenance of a European patent which includes such a feature. [read post]
26 Sep 2007, 1:04 pm
The '482 patent further discloses that: The following adjuvant materials, for example, reduced the stability of the compounds (I) and should be avoided in the preparation of pharmaceutical compositions: modified maize starch, sodium croscarmelose, glycerol behenic acid ester, methacrylic acid co-polymers (types A and C), anion exchangers titanium dioxide, and silica gels such as Aerosil 200. [read post]